.png)
.png)
BIA Brexit Briefing Seminar - Regulation
This seminar has been postponed. A new date will be announced soon - please email if you have any questions.
This seminar will aim to inform, guide and facilitate discussion around medicines regulation and preparation for Brexit, and relocation of the EMA. Legal and regulatory experts will join BIA and member biotechnology companies to provide insight and informed discussion around the key issues facing innovative life science organisations.
Fieldfisher
Riverbank House
2 Swan Lane
London
EC4R 3TT
Nearest stations: London Cannon Street, Monument, London Bridge
09:30 - 10:00 Registration and refreshments
10:00 - 11:30 Expert insight
11:30 - 12:00 Discussion and Q&A
12:00 - 13:00 Networking and lunch
Nicole Jadeja
Nicole is a life sciences lawyer who enjoys resolving IP disputes and providing strategic IP advice, as well as working at the interface between IP, commercial and regulatory law.
Laura Collister
Laura joined BioIndustry Association in July 2016 as interim Head of Communications and Public Affairs for a year, where her work includes BIA’s Brexit activity. Laura recently worked at GSK in the UK operating company as Head of Government Affairs. Laura also worked at Vodafone, Unilever, the Cooperative Group, ABHI and Fleishman Hillard in public affairs and communications roles.
Dr Virginia Acha
Virginia (Ginny) has worked in industry and academia throughout her career, combining interests in science policy research and innovation performance within and across organizations. She recently joined MSD to lead regulatory policy efforts for innovation that will lead to better treatment for patients in Europe, the Middle East, Africa and Asia. In particular, she is supporting work on science policy, regulatory innovation and integrated evidence generation. Before joining MSD, Ginny was the senior spokesman for the industry in the UK for research, medical and innovation policy. She was responsible for ABPI’s work on BREXIT for the life sciences sector. Previously, Ginny worked for Amgen in global regulatory policy and for Pfizer working on policy development in science and innovation in healthcare.
Kindly hosted by
